| Thursday February 13 |
| 0900-1700 | Arrivals
Industry ad-boards
|
| 1630-1930 | Registration
|
| 1700-1900 | CRS business meeting
|
| 1900-2030 | Welcome reception |
| Friday February 14 |
| 0600-0630 | Breakfast
|
| 0600-1015 | Registration
|
| 0630-0900 | Scientific session 1
At the end of this session, participants will be able to:
- Understand how to classify vitreomacular disease
- Understand the importance of choroidal thickness in macular disease
- Identify new developments in macular telangiectasia
- Knowledgeably discuss vitreomacular diseases and macular diseases that effect choroidal thickness
|
- Dr. Jay Duker: A new, international classification for diseases of the vitreomacular interface
- Dr. Jay Duker: Choroidal thickness in macular disease
- Dr. Emily Chew: Update on macular telangiectasia
- Panel discussion: Vitreomacular interface and choroidal disease
- Case presentations and discussion
|
| 0910-1010 | Co-developed accredited symposium: Treatment of diabetic macular edema
At the end of this session, participants will be able to:
|
- Dr. David Maberley: Overview of COS Clinical Practice Guidelines for DME
- Case presentations: Dr. Tom Sheidow
- Panelists: Dr. Jay Duker , Dr. Carl Regillo, Dr. Stan Shortt, Dr. Sohel Somani, Dr. Murray Erasmus
This symposium was co-developed with the Canadian Ophthalmological Society and Novartis Pharmaceuticals Canada Inc. and was planned to ensure that the evidence presented is valid, objective and balanced.
|
| 1500-1815 | Registration
|
| 1530-1600 | Refreshment break
|
| 1600-1830 | Scientific session 2
At the end of this session, participants will be able to:
- Incorporate into their clinical practice key information from AREDS II
- Understand the impact of cataract surgery on progression of macular degeneration
- Outline the genetic risk markers for AMD and the impact they have vitamin therapy
- Understand the shortcomings and possible benefits of stem therapy for geographic atrophy in AMD
|
- Introduction
- Dr. Emily Chew: AREDS II - information for the clinician
- Dr. Carl Awh: Genetic risk markers for AMD and response to antioxidant and zinc supplementation
- Dr. Emily Chew: AMD Progression after cataract surgery (possibly genetic testing in AMD)
- Dr. Carl Regillo: Stem cell therapy for advanced atrophic macular degeneration
- Panel discussion: Prevention, testing and treatment for macular degeneration
|
| 1900 | Dinner at the Roundhouse Lodge (tickets required) |
| Saturday February 15 |
| 0600-0630 | Breakfast
|
| 0600-1015 | Registration
|
| 0630-0900 | Scientific session 3
At the end of this session, participants will be able to:
- Outline the mechanical principles in vitreoretinal surgery
- Incorporate into their practice retinal surgical tips and tricks
- Describe the current management of retained lens material
- List the benefits of sclera fixated IOL for aphakia
|
- Welcome and introductions
- Dr. Carl Awh: Mechanical principles in vitreoretinal surgery
- Dr. Carl Awh: Retinal surgical tips and tricks
- Dr. Carl Regillo: Current management of retained lens material
- Dr. Mark Greve: Benefits of scleral fixated IOL for aphakia
- Panel discussion: Vitreoretinal surgery
- Case presentations and discussion
|
| 0910-1010 | Co-developed accredited symposium: New treatment option for symptomatic vitreomacular adhesion (VMA)
At the end of this session, participants will be able to:
- Identify new treatment options in the management of diseases of the vitreoretinal interface
- Assess patient baseline characteristics associated with successful outcomes after treatment with ocriplasmin
- Integrate pharmacologic vitreolysis as a new treatment option for patients with symptomatic VMA
|
- Dr. Jay Duker: Clinical trial overview and predictors of response
- Dr. Deepa Yoganathan: Review of recent published data
- Dr. David Chow: Canadian clinical experience
This symposium was co-developed with the Canadian Ophthalmological Society and Alcon Canada Inc. and was planned to ensure that the evidence presented is valid, objective and balanced.
|
| 1530-1815 | Registration
|
| 1530-1600 | Refreshment break
|
| 1600-1900 | Scientific session 4
At the end of this session, participants will be able to:
- Integrate into their practice lessons learned from interesting uveitis cases
- Compare and contrast treatments of intermediate, posterior and pan-uveitis
- Identify which lesions to treat and which not to treat in wet AMD
- Discuss the latest treatment algorithms in wet macular degeneration
|
- Dr. Farzin Forooghian: Treatment of intermediate, posterior and pan-uveitis
- Dr. Farzin Forooghian: Interesting uveitis cases
- Panel discussion: Treatment of intermediate, posterior and pan-uveitis
- Dr. Carl Regillo: Anti-Vegf maintenance therapy for neovascular AMD
- Panel discussion: Testing and treatment of wet macular degeneration
|
| Dinner on your own |
| Sunday February 16 |
| 0630-0700 | Breakfast
|
| 0630-1000 | Registration
|
| 0700-1000 | Scientific session 5
At the end of this session, participants will be able to:
- Assess their current case management knowledge through discussion of difficult retina cases
- Integrate into their practice knowledge from new developments in the management of unique retina cases
|
- Expanding the dialogue
- Case presentations & discussion
- Panel discussion
|
| 1000 | Adjourn |
We've gone mobile!